- Home
- CRSR vs AKBA Comparison
CRSR vs AKBA Comparison
Compare CRSR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSR
- AKBA
- Stock Information
- Founded
- CRSR 1994
- AKBA 2007
- Country
- CRSR United States
- AKBA United States
- Employees
- CRSR N/A
- AKBA N/A
- Industry
- CRSR Computer Manufacturing
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CRSR Technology
- AKBA Health Care
- Exchange
- CRSR Nasdaq
- AKBA Nasdaq
- Market Cap
- CRSR 958.7M
- AKBA 958.6M
- IPO Year
- CRSR 2020
- AKBA 2014
- Fundamental
- Price
- CRSR $9.35
- AKBA $3.85
- Analyst Decision
- CRSR Buy
- AKBA Strong Buy
- Analyst Count
- CRSR 6
- AKBA 5
- Target Price
- CRSR $10.00
- AKBA $6.90
- AVG Volume (30 Days)
- CRSR 459.9K
- AKBA 3.9M
- Earning Date
- CRSR 07-31-2025
- AKBA 08-07-2025
- Dividend Yield
- CRSR N/A
- AKBA N/A
- EPS Growth
- CRSR N/A
- AKBA N/A
- EPS
- CRSR N/A
- AKBA N/A
- Revenue
- CRSR $1,348,872,000.00
- AKBA $184,909,000.00
- Revenue This Year
- CRSR $14.40
- AKBA $26.88
- Revenue Next Year
- CRSR $9.76
- AKBA $44.34
- P/E Ratio
- CRSR N/A
- AKBA N/A
- Revenue Growth
- CRSR N/A
- AKBA N/A
- 52 Week Low
- CRSR $5.60
- AKBA $1.07
- 52 Week High
- CRSR $13.02
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- CRSR 55.33
- AKBA 62.44
- Support Level
- CRSR $9.21
- AKBA $3.81
- Resistance Level
- CRSR $9.86
- AKBA $4.08
- Average True Range (ATR)
- CRSR 0.32
- AKBA 0.15
- MACD
- CRSR -0.04
- AKBA -0.02
- Stochastic Oscillator
- CRSR 50.72
- AKBA 68.45
About CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.